---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-041225"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:49:14.890327+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ionis reports Phase 3 olezarsen results: 72% TG reduction, 85% fewer pancreatitis events

## Summary
- Primary endpoint met: up to 72% placebo-adjusted mean reduction in fasting triglycerides at 6 months, sustained through 12 months (p<0.001).
- 85% reduction in acute pancreatitis events (p<0.001); 86% of patients achieved TG <500 mg/dL, below risk threshold.
- Favorable safety profile; serious AEs lower in olezarsen (9-11%) vs placebo (14%); most common AE mild injection site reactions.
- sNDA for 50 mg and 80 mg doses to be submitted to FDA by end of 2025; PDUFA target action date in 2026.
- Data presented at AHA Scientific Sessions and simultaneously published in The New England Journal of Medicine.

## SEC filing metadata
- accession: 0001140361-25-041225
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036125041225/0001140361-25-041225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036125041225/ef20058520_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-041225
- JSON: https://secwatch.observer/filing/0001140361-25-041225.json
- Plain text: https://secwatch.observer/filing/0001140361-25-041225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.